Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut. - Huber H; Tausch E; Schneider C; Edenhofer S; von Tresckow J; Robrecht S; Giza A; Zhang C; Fürstenau M; Dreger P; Ritgen M; Illmer T; et al. (Blood, 2023)